Circle Pharma is a clinical-stage biopharmaceutical company based in South San Francisco, California, developing targeted macrocycle therapeutics for cancer. Its proprietary MXMO platform combines structure-based rational drug design and advanced synthetic chemistry to create intrinsically cell-permeable, orally bioavailable macrocycles against historically undruggable targets, with a pipeline focused on cyclins, key regulators of the cell cycle that drive many cancers. Lead program CID-078, an oral cyclin A/B RxL inhibitor, is in a Phase 1 trial in advanced solid tumors with RB1 alterations, and second program CID-165, a cyclin D1 RxL inhibitor, is expected to enter clinical development in early 2027 for ER-positive breast cancer.
1
Round
1
Industry
5
Tags
Sep 16, 2026
Latest raise
Funding activity · 1 round
Sep 16, 2026
$92.5M
Series C+
Led by The Column Group
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
